Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 95 от 154

Активно (без набиране) Фаза 1

A Trial of SHR-1139 in Healthy Volunteers

Psoriasis

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers

Начало: 19.08.2025 Край: 30.09.2026 Възраст: 18–55 г. Лечение

Australia Atridia Pty Ltd. NCT07078695

Активно (без набиране) Фаза 1

A Phase 1 Study of JADE101 in Healthy Participants

Healthy Volunteers

This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.

Начало: 17.08.2025 Край: 01.10.2026 Възраст: 18–55 г. Фундаментална наука

New Zealand Jade Biosciences, Inc. NCT07059312

Активно (без набиране) Фаза 1

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Pneumonia, Bacterial

This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.

Начало: 12.08.2025 Край: 09.06.2026 Възраст: 50–64 г. Превенция

Australia GlaxoSmithKline NCT07105722

Активно (без набиране) Ранна Фаза 1

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

Healthy Volunteers

The main objective is to assess the safety and tolerability of subcutaneous and intravenous injection forms of budoprutug in healthy volunteers.

Начало: 11.08.2025 Край: 01.06.2026 Възраст: 18–50 г. Фундаментална наука

Australia Climb Bio, Inc. NCT07090655

Активно (без набиране)

STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)

Respiratory Syncytial Virus (RSV) Respiratory Syncytial Virus Lower Respiratory Tract Disease Respiratory Tract Diseases +1

This Pfizer-sponsored real-world retrospective non-interventional study will be conducted within a research network comprised of independent hospitals across Australia using data collected during routine standard of care clinical encounters available in health records, supplemented with information from the official national immunisation registry, the Australian Immunisation Register. Additional data from accredited pathology laboratories will be included. There will be no active enrollment of study participants, no direct contact with study participants, and no collection of any primary data outside of the standard of care. This study will use a test negative design to evaluate real-world vaccine effectiveness of RSVpreF vaccination during pregnancy against RSV-associated outcomes in infants.

Начало: 11.08.2025 Край: 30.04.2027 Възраст: до 12 г.

Australia Pfizer NCT07122661

Активно (без набиране) Фаза 4

A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA

Optimal Absorption of Omega-3 Healthy

This is a randomised, double-blind, parallel, placebo-controlled study in healthy subjects to compare the absorption of two microalgal formulations, to a fish oil and a placebo.

Начало: 06.08.2025 Край: 01.12.2026 Възраст: 18–64 г. Друго

Australia RDC Clinical Pty Ltd NCT06629103

Активно (без набиране) Фаза 3

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Advanced Clear Cell Renal Cell Carcinoma

This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC).

Начало: 28.07.2025 Край: 29.07.2032 Възраст: от 18 г. Лечение

Australia, China, Georgia +3 AstraZeneca NCT07000149

Активно (без набиране) Фаза 2

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

Asthma (Diagnosis)

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate or severe asthma. WIN378 blocks the action of a protein called TSLP which causes inflammation in the lung and may contribute to your asthma control and symptoms. The study will test how doses of WIN378 are handled by your body (pharmacokinetics) and assess the safety of the medicine and will assess markers of asthma inflammation in your breath and in your blood, lung function and asthma control (pharmacodynamics).

Начало: 24.07.2025 Край: 01.10.2027 Възраст: 18–75 г. Лечение

Argentina, Australia, Bulgaria +5 Windward Bio NCT07120503

Активно (без набиране)

BIO|CONCEPT.CorSky, First in Human Study for the CorSky ICD Family

Tachycardia Heart Failure

The goal of this exploratory study is to test the preliminary safety and product performance of the new CorSky ICD family in subjects that require an ICD or cardiac resynchronization therapy with defibrillation (CRT-D). The study will be conducted at sites in Australia and New Zealand. It is planned to include 50 subjects in the study. Participants will visit sites at enrollment in the study, at implantation, pre-hospital discharge, 1- 3- and 12-month follow-up visits. At the visits the device will be interrogated and standard device measurements including those related to special features will be performed to assess the functionality of the device. Programming of the ICDs will be done according to the participant´s therapeutical needs.

Начало: 23.07.2025 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia Biotronik Australia Pty Ltd. NCT06840509

Активно (без набиране) Фаза 1

Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

Respiratory Syncytial Virus Immunization

The purpose of this study is to evaluate the safety and immunogenicity of different liponanaoparticle (LNP) formulations of modified ribonucleic acid (mRNA) vaccines using the RSV pre-F antigen in healthy participants 18 to 49 years of age. -Each participant will remain in the study for approximately 6 months. * The study intervention will be administered as a single intramuscular (IM) dose in the upper arm on Day 1 (D01). * The visit frequency will include 1 Screening Visit, 4 planned site visits to occur on D01, D03, D08, and D29, and 2 telephone calls to occur at Month (M)3 and M6.

Начало: 14.07.2025 Край: 26.02.2026 Възраст: 18–49 г. Превенция

Australia Sanofi NCT07071558

Активно (без набиране)

Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes

Diabetes Mellitus

The purpose of the study is to assess the safety and efficacy of a next generation automated insulin delivery algorithm in adults with type 2 diabetes aged 16-70 years old

Начало: 01.07.2025 Край: 01.05.2026 Възраст: 16–70 г. Лечение

New Zealand Insulet Corporation NCT07039981

Активно (без набиране) Фаза 2

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Hypertriglyceridemia

The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of the TG and RC in adults with elevated TG and RC.

Начало: 30.06.2025 Край: 01.12.2026 Възраст: 18–75 г. Лечение

Australia, Canada, New Zealand +1 Marea Therapeutics NCT07028749

Активно (без набиране) Фаза 1

A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19

COVID-19 Infection

The goal of this clinical trial is to learn if a new drug called PDI204, developed for treating or preventing COVID-19, is safe and well-tolerated in healthy volunteers. This is a first-in-human study. The main questions it aims to answer are: Is PDI204 safe and well-tolerated in healthy people? How long for and how does the body interact with PDI204? Researchers will compare side effects in people who receive PDI204 and in those who receive a placebo (a look-alike substance that contains no drug) to see if and how many side-effects there are with PDI204. Researchers will also measure how long PDI204 can be detected in the blood. Participants will be asked to receive a single dose of PDI204. Participants will have to stay in the clinical center for the day of receiving the dose of PDI204 and will be discharged the next day. Participants will then need to come back to the clinical center for study visits on days 3, 5, 7 (+/-1), 15 (+/-1), 30 (+/-3), 60 (+/-3) and 90 (+/-7).

Начало: 27.06.2025 Край: 31.05.2026 Възраст: 18–65 г. Лечение

Australia University of Melbourne NCT06965751

Активно (без набиране) Фаза 3

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

Heterozygous Familial Hypercholesterolaemia

This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Начало: 10.06.2025 Край: 04.01.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +20 AstraZeneca NCT07000136

Активно (без набиране) Фаза 2

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Hidradenitis Suppurativa

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).

Начало: 09.06.2025 Край: 22.01.2029 Възраст: 18–75 г. Лечение

Argentina, Australia, Canada +12 Merck Sharp & Dohme LLC NCT06956235

Активно (без набиране)

Effects of Chestnuts on Postprandial Glycaemic Response

Postprandial Glycemia Insulin Resistance

Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols. Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.

Начало: 06.06.2025 Край: 30.04.2026 Възраст: 18–65 г. Друго

Australia Monash University NCT06960967

Активно (без набиране) Фаза 1

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).

Начало: 04.06.2025 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Canada, New Zealand Apogee Therapeutics, Inc. NCT07027527

Активно (без набиране) Фаза 3

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

Cardiovascular Disease

This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Начало: 28.05.2025 Край: 11.01.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +19 AstraZeneca NCT07000123

Активно (без набиране)

An Investigation to Evaluate Sound Coding Enhancements in Adult Cochlear Implant Recipients

Cochlear Implant Recipients Hearing Loss, Cochlear

This study will evaluate a range of experimental sound coding strategies that may improve hearing for cochlear implant recipients.

Начало: 27.05.2025 Край: 01.04.2030 Възраст: от 18 г. Фундаментална наука

Australia Cochlear NCT06867380

Активно (без набиране) Фаза 1

ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose

Healthy Volunteers

This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.

Начало: 19.05.2025 Край: 01.01.2027 Възраст: 18–65 г. Друго

New Zealand Oruka Therapeutics, Inc. NCT06944379

1 … 93 94 95 96 97 … 154